Intellia TherapeuticsNTLA
Recorded

Intellia Therapeutics Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Maury RaycroftBiotech Analyst

Hi, everyone. My name is Maury Raycroft, and I am one of the biotech analysts at Jefferies. I would like to welcome the management team of Intellia with us today. We have got the CEO, John Leonard, and the CFO, Edward Dulac. Thanks so much for joining us today.

John LeonardCEO

Great to be here. Great to be here.

Maury RaycroftBiotech Analyst

We are going to do a fireside chat format, so for those who are new to this story, if you can give a brief intro to Intellia.

John LeonardCEO

Sure. We are one of the original CRISPR companies, back in 2014, and we've pioneered the in vivo gene editing space. That's something that we've really focused on since the very beginning, developing a proprietary lipid nanoparticle platform and going after targets that are based in the liver. We've advanced to the point where we have one program for hereditary angioedema under a BLA review. I'm sure we'll be talking about that. And we're well into a phase III program for TTR amyloidosis of both cardiomyopathy and polyneuropathy.

Maury RaycroftBiotech Analyst

Great. Yeah, it's a good intro. You've got the HAE program that's in the final stages. It's under priority review. You've got a PDUFA scheduled for March 10, 2027. What's been the feedback from FDA, and have there been any information requests out of the ordinary, and how much additional follow-up phase III data is going into the filings?

John LeonardCEO

It's going very well. We're very pleased with the progress that we've made, as you pointed out. What the FDA has said is that, as of now or so far, they don't think there's a need for an advisory committee, which we thought was really good news. We were prepared for one should they want to do that as a first example. But nothing has been out of the ordinary. I think we are in a good position. The data's out there. I mean, the data's quite clean, and I don't think there's much of controversy in the filing.

Maury RaycroftBiotech Analyst

Got it. Okay. We view improving efficacy with longer follow-up, with attacks basically going to zero, and for patients to remain prophy-free as differentiating characteristic of your drug. Are there ways this can be leveraged in your prescribing label and guidelines, or is it more about having the data out there and then educating around it once approved?

John LeonardCEO

I think it's both. The data is quite compelling. When we show it to experts in the field, prescribers, I mean, they're very impressed by what they see. One thing that's been quite remarkable is physicians who have participated in the trials, whether it's phase I, II, or III, after they use the product, they become quite pleased with what they see in their patients. One of the feedbacks that we've gotten, which we talked about just last week at our IR event, is, and I think this is really fundamental to the story, is that patients recalibrate what they think is well controlled based on what the new experience is.

John LeonardCEO

The idea that they're able to get to, in the vast majority of cases, having no attacks and importantly, not having any other therapy, save some patients with rare exceptions who may need some on-demand therapy, that is like a new beginning for many of these patients. We think as the word gets out, patient to patient, and as doctors have access to the product and use it, that will be very, very important for uptake.

Ed DulacCFO

I'll just add one thing. Durability is a common conversation we have with patients, physicians, certainly even payers. You've seen what we think are beautiful curves on kallikrein, which is the protein we're knocking down. So we've provided those updates, and we're out four-plus years now, and so we're going to continue to follow those patients and share those updates, which I do think speaks to a lot of the key stakeholders here involved in the prescribing.

Maury RaycroftBiotech Analyst

Makes sense. We're not expecting any surprises on CMC and site inspections as you're part of the FDA's CMC pilot program. Is that the right way to think about it? Looking ahead, what do you expect COGS at scale to be for the program?

John LeonardCEO

Do you want to speak about COGS? You are the numbers guy.

Ed DulacCFO

I will talk about COGS, but not specifically. We are not going to talk about the details.

Ed DulacCFO

Right. I would say, just let us remind ourselves where we are.

Ed DulacCFO

It is a synthetic product to manufacture, and because we are a highly effective one-time therapy, scale is really not an issue. We have had infrastructure in place for quite some time. We are obviously ready for commercialization. From a cost of goods perspective, we haven't named the price yet, and we are not going to do that today, of course, but it is going to be a very high-margin product. We love the overall clinical profile, but we also love the financial profile, and I am sure we will talk about later just financing the company, the capital needs, the cash runway, et cetera. But it is going to be a very strong, profitable product that is going to have a big contribution margin for us.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day